Technical Articles

This article systematically elaborates on the molecular characteristics and clinical distribution of KRAS G12D, the most common KRAS mutation subtype, as well as its mechanisms in driving tumorigenesis. It provides an in-depth analysis of the challenges in drug development due to the lack of covalent binding sites and unique GTP hydrolysis kinetics. Additionally, it focuses on how TCR-T cell therapy-based immunotherapy strategies can achieve precise targeting of this "undruggable" target using MHC-peptide tetramer technology.